创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

张玉琴, 孙业平, 齐建勋. 抗病毒纳米颗粒疫苗的研究进展[J]. 药学进展, 2022, 46(10): 751-760. DOI: 10.20053/j.issn1001-5094.2022.10.005
引用本文: 张玉琴, 孙业平, 齐建勋. 抗病毒纳米颗粒疫苗的研究进展[J]. 药学进展, 2022, 46(10): 751-760. DOI: 10.20053/j.issn1001-5094.2022.10.005
ZHANG Yuqin, SUN Yeping, QI Jianxun. Research Progress of Antiviral Nanoparticle Vaccines[J]. Progress in Pharmaceutical Sciences, 2022, 46(10): 751-760. DOI: 10.20053/j.issn1001-5094.2022.10.005
Citation: ZHANG Yuqin, SUN Yeping, QI Jianxun. Research Progress of Antiviral Nanoparticle Vaccines[J]. Progress in Pharmaceutical Sciences, 2022, 46(10): 751-760. DOI: 10.20053/j.issn1001-5094.2022.10.005

抗病毒纳米颗粒疫苗的研究进展

Research Progress of Antiviral Nanoparticle Vaccines

  • 摘要: 疫苗是防控传染病最为经济有效的手段之一。通过疫苗接种,人类已消灭天花和脊髓灰质炎疾病。然而大多数危害人类的病毒仍缺乏有效的疫苗,同时某些RNA病毒,如流感病毒、新型冠状病毒(SARS-CoV-2)的高突变性致使现有疫苗效力不断减弱,因此开发安全、高效的通用疫苗十分必要。纳米颗粒疫苗可展示多重不同优势抗原表位从而诱导更强更广谱的免疫保护,故纳米颗粒疫苗备受关注。综述纳米颗粒疫苗给药方式及其在激发宿主免疫应答、递呈抗原和递送药物方面的优势,重点介绍几种常用纳米颗粒疫苗载体及其优缺点,以及针对SARS-CoV-2的纳米颗粒疫苗的最新临床进展,旨在为新型抗病毒疫苗的研发提供参考。

     

    Abstract: Vaccines are one of the most cost-effective means of controlling and preventing infectious diseases. Until now humans have eradicated smallpox and polio through vaccination. Still, most viruses that harm humans lack effective vaccines. In addition, certain RNA viruses such as influenza viruses and novel coronaviruses have led to immune escape of existing vaccines due to their mutability. To this end, the development of safe and efficient universal vaccines is urgently needed. Nanoparticle vaccines can exhibit multiple different dominant antigen epitopes to induce stronger and broader-spectrum immune protection. The review expounds the administration routes of nanoparticle vaccines, the advantages of nanoparticle vaccines from the perspective of stimulating the immune response of the host, advantages of nanoparticle vaccines for presenting antigens and delivering drugs, summarizes several commonly used nanoparticle vaccine carriers and their advantages and disadvantages, and introduces the latest clinical progress of several SARS-CoV-2 nanoparticle vaccines, in order to provide reference for the development of new antiviral vaccines.

     

/

返回文章
返回